Abstract
HIV replication in humans proceeds with substantial viral RNA levels in plasma. Antiretroviral therapy results in suppression but not eradication of HIV infection. Continuous therapy is essential for durable clinical responses. Discontinuing antiretroviral therapy results in prompt rebound in viremia. The source of HIV during suppressive therapy and mechanisms of persistence remain uncertain. Sensitive assays for HIV have been useful in quantifying viremia in response to antiretroviral therapy and in experimental studies of drug intensification, drug simplification, and potential anatomic sanctuary site investigations. As clinical eradication strategies move forward, robust, sensitive quantitative assays for HIV at low levels represent essential laboratory support modalities. Here we describe in detail an assay for HIV-1 RNA with single-copy sensitivity.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ibrahim SM, Aitichou M, Hardick J, Blow J, O’Guinn ML, Schmaljohn C (2011) Detection of Crimean-Congo hemorrhagic fever, Hanta, and sandfly fever viruses by real-time RT-PCR. Methods Mol Biol 665:357–368
Stahlberg A, Kubista M, Aman P (2011) Single-cell gene-expression profiling and its potential diagnostic applications. Expert Rev Mol Diagn 11(7):735–740
Guarino A, Giannattasio A (2011) New molecular approaches in the diagnosis of acute diarrhea: advantages for clinicians and researchers. Curr Opin Gastroenterol 27(1):24–29
O’Connor L, Glynn B (2010) Recent advances in the development of nucleic acid diagnostics. Expert Rev Med Devices 7(4):529–539
Khot PD, Fredricks DN (2009) PCR-based diagnosis of human fungal infections. Expert Rev Anti Infect Ther 7(10):1201–1221
Pasqualini L, Mencacci A, Leli C et al (2012) Diagnostic performance of a multiple real-time PCR assay in patients with suspected sepsis hospitalized in an internal medicine ward. J Clin Microbiol 50(4):1285–1288
Lyles RH, Chu C, Mellors JW et al (1999) Prognostic value of plasma HIV RNA in the natural history of Pneumocystis carinii pneumonia, cytomegalovirus and Mycobacterium avium complex. Multicenter AIDS Cohort Study. AIDS 13(3):341–349
Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272(5265): 1167–1170
Tarwater PM, Gallant JE, Mellors JW et al (2004) Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. AIDS 18(18):2419–2423
Dewar RL, Highbarger HC, Sarmiento MD et al (1994) Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 170(5):1172–1179
Elbeik T, Alvord WG, Trichavaroj R et al (2002) Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5. J Acquir Immune Defic Syndr 29(4):330–339
Highbarger HC, Alvord WG, Jiang MK et al (1999) Comparison of the Quantiplex version 3.0 assay and a sensitized Amplicor monitor assay for measurement of human immunodeficiency virus type 1 RNA levels in plasma samples. J Clin Microbiol 37(11):3612–3614
Swanson P, Holzmayer V, Huang S et al (2006) Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA Quantitative assays. J Virol Methods 137(2): 184–192
Katsoulidou A, Petrodaskalaki M, Sypsa V et al (2006) Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: comparison of the new COBAS TaqMan HIV-1 with three current HIV-RNA assays–LCx HIV RNA quantitative, VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor v1.5. J Virol Methods 131(2):168–174
Berger A, Scherzed L, Sturmer M, Preiser W, Doerr HW, Rabenau HF (2005) Comparative evaluation of the Cobas Amplicor HIV-1 Monitor Ultrasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples. J Clin Virol 33(1):43–51
Dornadula G, Zhang H, VanUitert B et al (1999) Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282(17):1627–1632
Wong JK, Hezareh M, Gunthard HF et al (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278(5341):1291–1295
Davey RT Jr, Bhat N, Yoder C et al (1999) HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 96(26):15109–15114
Maldarelli F (2011) Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication. Curr Opin HIV AIDS 6(1):49–56
Hatano H, Delwart EL, Norris PJ et al (2010) Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 24(16):2535–2539
Palmer S, Wiegand AP, Maldarelli F et al (2003) New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41(10):4531–4536
Maldarelli F, Palmer S, King MS et al (2007) ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3(4):e46
Palmer S, Maldarelli F, Wiegand A et al (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 105(10):3879–3884
Dinoso JB, Kim SY, Wiegand AM et al (2009) Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 106(23):9403–9408
Gandhi RT, Zheng L, Bosch RJ et al (2010) The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 7(8)
Hatano H, Hayes TL, Dahl V et al (2011) A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 203(7):960–968
McMahon D, Jones J, Wiegand A et al (2010) Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 50(6):912–919
Buzon MJ, Massanella M, Llibre JM et al (2010) HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16(4):460–465
Dahl V, Lee E, Peterson J et al (2011) Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis 204(12):1936–1945
Josefsson L, King MS, Makitalo B et al (2011) Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci USA 108(27):11199–11204
Grant PM, Palmer S, Bendavid E et al (2009) Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. J Clin Virol 46(4):305–308
Wilkin TJ, McKinnon JE, DiRienzo AG et al (2009) Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis 199(6):866–871
Archin NM, Eron JJ, Palmer S et al (2008) Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 22(10):1131–1135
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Wiegand, A., Maldarelli, F. (2014). Single-Copy Quantification of HIV-1 in Clinical Samples. In: Vicenzi, E., Poli, G. (eds) Human Retroviruses. Methods in Molecular Biology, vol 1087. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-670-2_20
Download citation
DOI: https://doi.org/10.1007/978-1-62703-670-2_20
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-669-6
Online ISBN: 978-1-62703-670-2
eBook Packages: Springer Protocols